{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+2%2C+Cohort+2&page=2",
    "query": {
      "intervention": "Part 2, Cohort 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+2%2C+Cohort+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T01:07:29.244Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02014337",
      "title": "Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Epithelial Cancer Recurrent",
        "Sarcoma",
        "Non-small Cell Lung Cancer",
        "Carcinoma, Transitional Cell",
        "Prostate Cancer",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Mifepristone and Eribulin in combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-01",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Royal Oaks",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02014337"
    },
    {
      "nct_id": "NCT07723703",
      "title": "Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukaemia",
        "High Risk Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "AMX-883",
          "type": "DRUG"
        },
        {
          "name": "Posaconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amphista Therapeutics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2026-09-30",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07723703"
    },
    {
      "nct_id": "NCT05241873",
      "title": "(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Neoplasm Malignant",
        "Carcinoma, Non-Small-Cell Lung",
        "Respiratory Tract Neoplasms",
        "Neoplasms",
        "Neoplasms by Site",
        "Lung Diseases",
        "Respiratory Tract Disease",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Adenocarcinoma",
        "Carcinoma",
        "Neoplasms by Histologic Type",
        "EGFR Exon 20 Mutation",
        "EGFR Exon 20 Insertion Mutation",
        "EGFR Activating Mutation",
        "Antineoplastic Agents",
        "Metastatic Lung Cancer",
        "Brain Metastases",
        "EGFR-mutated NSCLC",
        "EGFR Atypical Mutations, Including G719X and L861Q"
      ],
      "interventions": [
        {
          "name": "BLU-451",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2022-03-04",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05241873"
    },
    {
      "nct_id": "NCT04126031",
      "title": "Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gram-negative Bacterial Infection"
      ],
      "interventions": [
        {
          "name": "Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3",
          "type": "DRUG"
        },
        {
          "name": "Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "88 Days",
        "sex": "ALL",
        "summary": "0 Days to 88 Days"
      },
      "enrollment_count": 48,
      "start_date": "2020-01-14",
      "completion_date": "2022-12-30",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04126031"
    },
    {
      "nct_id": "NCT00730002",
      "title": "Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuropsychiatric Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Magnetic Resonance Angiography (MRA)",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "MRA",
          "type": "PROCEDURE"
        },
        {
          "name": "diffusion Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "perfusion imaging.",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 66,
      "start_date": "2008-03",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-12-14",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730002"
    },
    {
      "nct_id": "NCT04616677",
      "title": "A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "JNJ-42847922",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-03-31",
      "completion_date": "2022-10-18",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04616677"
    },
    {
      "nct_id": "NCT06827236",
      "title": "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Breast Cancer",
        "Unresectable Breast Carcinoma",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BNT323",
          "type": "DRUG"
        },
        {
          "name": "BNT327",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 380,
      "start_date": "2025-04-23",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 27,
      "location_summary": "Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06827236"
    },
    {
      "nct_id": "NCT03708328",
      "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Metastatic Melanoma",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Small Cell Lung Cancer (SCLC)",
        "Esophageal Squamous Cell Carcinoma (ESCC)"
      ],
      "interventions": [
        {
          "name": "Lomvastomig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2018-10-15",
      "completion_date": "2024-07-09",
      "has_results": true,
      "last_update_posted_date": "2025-08-20",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03708328"
    },
    {
      "nct_id": "NCT04313400",
      "title": "Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "1.1% w/w AMTX-100 CF-part1",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "1.1% w/w AMTX-100 CF3-part2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amytrx Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2020-03-10",
      "completion_date": "2024-01-02",
      "has_results": true,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 11,
      "location_summary": "Cerritos, California • Encino, California • Long Beach, California + 8 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04313400"
    },
    {
      "nct_id": "NCT05094336",
      "title": "A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced MTAP-null Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Anvumetostat",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Comparator Anvumetostat Test Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 329,
      "start_date": "2022-02-01",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-09-30T01:07:29.244Z",
      "location_count": 30,
      "location_summary": "Duarte, California • Glendale, California • Oxnard, California + 24 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Margate",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05094336"
    }
  ]
}